The 10-second takeaway
For the quarter ended March 31 (Q1), Antares Pharma crushed expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share improved to zero.
Margins increased across the board.
Antares Pharma reported revenue of $6.9 million. The three analysts polled by S&P Capital IQ looked for a top line of $4.4 million on the same basis. GAAP reported sales were 92% higher than the prior-year quarter's $3.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.00. The one earnings estimate compiled by S&P Capital IQ forecast -$0.02 per share. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 71.0%, 1,170 basis points better than the prior-year quarter. Operating margin was -1.4%, 3,810 basis points better than the prior-year quarter. Net margin was -1.1%, 3,760 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $3.6 million. On the bottom line, the average EPS estimate is -$0.02.
Next year's average estimate for revenue is $26.1 million. The average EPS estimate is -$0.03.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members out of 183 rating the stock outperform, and 12 members rating it underperform. Among 20 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $3.65.
Over the decades, small-cap stocks like Antares Pharma have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Antares Pharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.